Personalis (NASDAQ:PSNL) Research Coverage Started at Lake Street Capital

Lake Street Capital began coverage on shares of Personalis (NASDAQ:PSNL) in a note issued to investors on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $4.00 price target on the stock. Lake Street Capital’s target price indicates a potential upside of 158.06% from the company’s current price.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $3.50 price target on shares of Personalis in a research note on Thursday, April 11th.

Personalis Price Performance

NASDAQ:PSNL opened at $1.55 on Tuesday. The stock’s 50-day moving average is $1.45 and its two-hundred day moving average is $1.43. The stock has a market cap of $78.28 million, a PE ratio of -0.69 and a beta of 1.95. Personalis has a fifty-two week low of $0.89 and a fifty-two week high of $2.60.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $19.68 million for the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative net margin of 147.38% and a negative return on equity of 61.42%. On average, equities research analysts anticipate that Personalis will post -1.58 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

Several large investors have recently made changes to their positions in PSNL. Prime Capital Investment Advisors LLC acquired a new stake in shares of Personalis in the 3rd quarter valued at $36,000. Pathstone Family Office LLC raised its holdings in Personalis by 149.3% during the third quarter. Pathstone Family Office LLC now owns 37,081 shares of the company’s stock valued at $45,000 after buying an additional 22,204 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Personalis in the fourth quarter worth about $152,000. Bruce & Co. Inc. lifted its position in shares of Personalis by 100.0% in the fourth quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $630,000 after buying an additional 150,000 shares during the last quarter. Finally, State of Michigan Retirement System boosted its stake in shares of Personalis by 11.3% during the 1st quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock worth $736,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.